8/20/2010

Human Genome Sciences and GlaxoSmithKline received priority-review status from the FDA for Benlysta, their treatment for systemic lupus. Benlysta, generically known as belimumab, "is the first medicine for lupus that has completed Phase III trials with positive results," a GSK official said.

Related Summaries